相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE
Matthew G. Mei et al.
BLOOD (2022)
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
Sarah Reinke et al.
BLOOD (2020)
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
R. Garcia-Sanz et al.
ANNALS OF ONCOLOGY (2019)
Optimizing therapy in advanced-stage Hodgkin lymphoma
Sean H. Lim et al.
BLOOD (2018)
Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis
Hugo J. A. Adams et al.
ANNALS OF HEMATOLOGY (2016)
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
Alison J. Moskowitz et al.
LANCET ONCOLOGY (2015)
Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma
Andreas Josting et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
T Baetz et al.
ANNALS OF ONCOLOGY (2003)
分享论文
